Get the latest tech news
‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts
The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, investors said.
While a federal judge on Friday extended a temporary pause to the policy in response to legal challenges from 22 attorneys general, some in the biotech industry see the clamp down on costs as risking slower research progress at a time when the U.S. is seeking to maintain its position as a life sciences leader. In supplemental guidance, the agency noted that most private foundations cover indirect costs at “substantially lower” rates than the federal government, and universities accept grants from them nonetheless. The impact likely won’t be “evenly distributed” either, hitting smaller schools harder than ones with much larger endowments, noted Lindy Fishburne, a managing partner at Breakout Ventures, a firm specializing in seed and Series A rounds.
Or read this on r/technology
